- Policy
- Patients with SCLS shouldn't get Janssen vaccine
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- The MFDS said Janssen COVID-19 vaccine should not be vaccinated for people with a history of Systemic Capillary Leak Syndrome (SCLS). This is in accordance with the European EMA recommendation and is similar to the action that was taken on the AstraZeneca vaccine on the 14th of last month. The MFDS released the Dear Healthcare Professi
- Policy
- Generic for Galvusmet was first approved
- by Lee, Tak-Sun Jul 16, 2021 05:54am
- The timing of the sale varies depending on the results of the Supreme Court's lawsuit against the validity of the patent. Hanmi has been approved for the first time in Korea as a generic for Galvusmet, a diabetes complex affiliated with Novartis' DPP-4 inhibitor. Hanmi developed Vildagliptin HCl and licensed both single and multi-drugs in
- Company
- Novartis most challenged for its patents, followed by Pfizer
- by Kim, Jin-Gu Jul 16, 2021 05:54am
- Among pharmaceutical companies, Novartis was found to have received the most amount of patent challenges since 2016. Over the past five and a half years, 33 generic companies had filed a total of 121 patent suits against Novartis' 15 patents on 8 products. In addition to Novartis, generic companies also targeted Pfizer, Boehringer Ingehei
- Policy
- Kymriah's benefit is urgently needed
- by Lee, Jeong-Hwan Jul 15, 2021 07:07pm
- Leukemia patients have urged rapid health insurance registration of the first end-stage leukemia-Lymphoma CAR-T treatment, Kymriah. Korea Leukmia patients organization asked the government to register Kymriah's benefit and pharmaceutical companies to come up with reasonable financial burdens to strengthen access to medicines for leukemia
- Company
- Xospata is approved as a targeted anti-cancer drug
- by Eo, Yun-Ho Jul 15, 2021 07:06pm
- The emergence of FLT3 targeted anticancer drugs is also causing new changes in the area of acute myeloid leukemia, which lacked treatment options. Chronic Myeloid Leukemia (CML), which was considered incurable, has benefited many patients from the commercialization of the targeted anti-cancer drug Glivec(Imatinib), but Acute Myeloid Leukem
- Opinion
- The patient's life comes first
- by Lee, Jeong-Hwan Jul 15, 2021 07:06pm
- On March 5, the MFDS approved Kymriah(Tisagenlecleucel), the world's first treatment for CAR-T, as the first advanced bio-medicine under the Advanced Regenerative Bio Act. Targets are patients with B-cell acute lymphocytic leukemia and submicrobial giant B-cell lymphoma under the age of 25 who are recurrent and nonresponsive. Kymriah was a
- Company
- Keytruda overcomes its 4-year hurdle, with Tecentriq
- by Eo, Yun-Ho Jul 15, 2021 06:30am
- The immunotherapy ‘Keytruda’ finally overcame one giant hurdle for its reimbursement, with ‘Tecentriq.’ According to industry sources, the PD-1 inhibitors &8211; MSD Korea’s ‘Ketyruda (pembrolizumab) and Roche Korea’s ‘Tecentriq (atezolizumab)’ &8211; passed deliberations by the Health Insurance Review & Assessment Service’s C
- Company
- Will Rivoceranib+Iressa really be a game changer ?
- by Jul 14, 2021 06:26pm
- Can Rivoceranib+Iressa therapy really be a game changer? This is the title of the press release distributed by HLB on the 9th. "We have confirmed high synergy with the first-generation blockbuster EGFR TKI drug in phase 3 clinical trials," HLB said. "We expect a next-generation treatment due to a complete improvement in one person and PFS.
- Company
- Bavencio can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 14, 2021 06:03am
- Merck and Pfizer’s immunotherapy ‘Bavencio’ can now be prescribed at general hospitals. According to industry sources, the PD-L1 inhibitor Bavencio (avelumab) passed the Drug Committees (DCs) of the Big-5s general hospitals in Korea - Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, Sams
- Company
- Will a new reimbursement model be introduced for Zolgensma?
- by Jul 14, 2021 06:03am
- The move to list Novartis’s new drug ‘Zolgensma (onasemnogene abeparvovec-xioi)’ for reimbursement benefits is now underway. The industry’s eyes are on which types of the RSA scheme will be combined for this ultra-high-priced ‘dream drug.’ Whether Zolgensma will be listed for insurance benefits is the focus of attention in the indus
